Effect and mechanism of quercetin or quercetin‐containing formulas against COVID ‐19: From bench to bedside
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8175 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Phytotherapy Research, 2024. Verfasst von Jhong Yuan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Quercetin, COVID-19 Drug Treatment, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 192 Literaturangaben.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has caused the global coronavirus disease 2019 (COVID‐19) pandemic since 2019. Immunopathogenesis and thromboembolic events are central to its pathogenesis. Quercetin exhibits several beneficial activities against COVID‐19, including antiviral, anti‐inflammatory, immunomodulatory, antioxidative, and antithrombotic effects. Although several reviews have been published, these reviews are incomplete from the viewpoint of translational medicine. The authors comprehensively evaluated the evidence of quercetin against COVID‐19, both basically and clinically, to apply quercetin and/or its derivatives in the future. The authors searched the PubMed, Embase, and the Cochrane Library databases without any restrictions. The search terms included COVID‐19, SARS‐CoV‐2, quercetin, antiviral, anti‐inflammatory, immunomodulatory, thrombosis, embolism, oxidative, and microbiota. The references of relevant articles were also reviewed. All authors independently screened and reviewed the quality of each included manuscript. The Cochrane Risk of Bias Tool, version 2 (RoB 2) was used to assess the quality of the included randomized controlled trials (RCTs). All selected studies were discussed monthly. The effectiveness of quercetin against COVID‐19 is not solid due to methodological flaws in the clinical trials. High‐quality studies are also required for quercetin‐containing traditional Chinese medicines. The low bioavailability and highly variable pharmacokinetics of quercetin hinder its clinical applications. Its positive impact on immunomodulation through reverting dysbiosis of gut microbiota still lacks robust evidence. Quercetin against COVID‐19 does not have tough clinical evidence. Strategies to improve its bioavailability and/or to develop its effective derivatives are needed. Well‐designed RCTs are also crucial to confirm their effectiveness in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- PhD Program in Toxicology, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID-Profile: Huei Syun Wang
Zitieren
APA
Chen, J. Y., Huang, T. R., Hsu, S. Y., Huang, C. C., Wang, H. S., & Chang, J. S. (2024). Effect and mechanism of quercetin or quercetin‐containing formulas against COVID ‐19: From bench to bedside. Phytotherapy Research. https://doi.org/10.1002/ptr.8175
Vancouver
Chen JY, Huang TR, Hsu SY, Huang CC, Wang HS, Chang JS. Effect and mechanism of quercetin or quercetin‐containing formulas against COVID ‐19: From bench to bedside. Phytotherapy Research. 2024. doi:10.1002/ptr.8175
BibTeX
@article{Chen2024,
author = {Chen, Jhong Yuan and Huang, Tsung Rung and Hsu, Shih Yun and Huang, Ching Chun and Wang, Huei Syun and Chang, Jung San},
title = {Effect and mechanism of quercetin or quercetin‐containing formulas against COVID ‐19: From bench to bedside},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8175}
}
EUVIMED